Research > Candy – ADHD, Autism & Epilepsy
The Candy Project started on 1 January 2020 with an end date of 31 December 2024. During this time, ADHD Europe gave input as described below with our member organisation, ADDISS to disseminate and share information on our European communication channels and more. Funding for this project was awarded via the European Union’s Horizon 2020 research and innovation programme under the Grant agreement ID: 847818.
Andrea Bilbow, past President of ADHD Europe (2014-2020) was responsible for the collaboration of ADDISS (national organisation based in UK, partner of the research consortium) and our ourselves, ADHD Europe during the timeframe of the project.
Patient support organisations help individual families with evidenced-based information when available via research consortia such as the ‘Candy’ project once released into the public domain. The information can range from Neurodevelopmental disorders (NDDs), autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and intellectual disability (ID) that are clinically heterogeneous, that often co-occur, affect ~15% of the EU population; and are associated with somatic illnesses (e.g. epilepsy, autoimmune and gastrointestinal disease) that lead to a significant increase in morbidity and mortality for individuals and families.
These scientific outcomes gave the opportunities for ourselves as support organisations to voice the actual lived experiences of people living with various conditions for researchers to gain insight and knowledge from support organisatoins.
Our role in the ‘Candy’ project is attending various workshops and annual partner meetings (face-to-face and online) when research was presented with outcomes to all project partners. The project’s multi-disciplinary team of world leading academics SMEs are working on the following
1) identify novel mechanisms underpinning NDDs and their multi-morbidity
2) develop new strategies for prevention and treatment
3) deliver novel biomarkers to guide early diagnosis, stratification and/or treatment monitoring
4) provide open-access databases, translational test batteries, and tools and targets for valorisation.
In the hope, that together we will transform the landscape for people with NDDs and make possible personalized medicine approaches that target particular mechanisms, in specific subgroups of individuals and at different life stages.
Thank you for visiting our website below are references which contains information about the facts of ADHD, book recommendations for all, common questions and answers about ADHD, articles and videos by International Experts sharing their medical knowledge and best practices, literature and scientific publications, Clinical Practice Guidelines for Diagnosis & Treatment of ADHD, diagnositic tools, ADHD Europe Official Declarations (In the Workplace, Girls & Women, Help! My Teenager is Becoming an Adult), ADHD Europe survey about the situation with regards to Access to Diagnosis & Treatment in Europe, ADHD Awareness, ADHD Research.
ADHD Europe collaborate with global coalitions whot together with us to tackle issues to combat stigma & discrimination by sharing information which is informative for the public and can be used in society.
One of our key priorities is to promote the collaboration of scientific research into ADHD with evidence-based information